What is Zacks Research’s Estimate for BHC Q3 Earnings?

Bausch Health Companies Inc. (NYSE:BHCFree Report) – Stock analysts at Zacks Research raised their Q3 2025 EPS estimates for shares of Bausch Health Companies in a research note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now anticipates that the company will earn $1.15 per share for the quarter, up from their prior estimate of $1.12. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.25 EPS.

Bausch Health Companies (NYSE:BHCGet Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the business posted $1.03 EPS. The business’s revenue was up 12.2% compared to the same quarter last year.

BHC has been the topic of a number of other research reports. Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Finally, Evercore ISI raised Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.75.

Check Out Our Latest Stock Analysis on Bausch Health Companies

Bausch Health Companies Stock Performance

Shares of BHC stock opened at $7.47 on Friday. The company has a market cap of $2.70 billion, a P/E ratio of -15.56 and a beta of 0.69. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The stock has a 50 day simple moving average of $8.34 and a two-hundred day simple moving average of $7.27.

Institutional Trading of Bausch Health Companies

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mackenzie Financial Corp boosted its holdings in Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after acquiring an additional 1,252,834 shares during the last quarter. LMR Partners LLP bought a new position in shares of Bausch Health Companies during the third quarter valued at about $3,264,000. Clearline Capital LP purchased a new position in Bausch Health Companies during the second quarter worth about $6,881,000. Intact Investment Management Inc. bought a new stake in Bausch Health Companies in the 3rd quarter worth about $1,543,000. Finally, XTX Topco Ltd purchased a new stake in Bausch Health Companies in the 3rd quarter valued at about $938,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Recommended Stories

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.